New antibiotic beats superbugs at their own game

Jul 03, 2008
Ceftobiprole Effective Against VRSA
Strains of bacteria that are resistant to the antibiotic vancomycin grow easily in its presence (top), but are completely eliminated (bottom) when exposed to Ceftobiprole. Credit: The Rockefeller University

The problem with antibiotics is that, eventually, bacteria outsmart them and become resistant. But by targeting the gene that confers such resistance, a new drug may be able to finally outwit them. Rockefeller University scientists tested the new drug, called Ceftobiprole, against some of the deadliest strains of multidrug-resistant Staphylococcus aureus (MRSA) bacteria, which are responsible for the great majority of staphylococcal infections worldwide, both in hospitals and in the community.

The research, to be published in the August 2008 issue of the journal Antimicrobial Agents and Chemotherapy and available online now, looked at how well Ceftobiprole worked against bacterial clones that had already developed resistance to other drugs. In every case, Ceftobiprole won. "It just knocked out the cells 100 percent," says the study's lead investigator, Alexander Tomasz, head of the Laboratory of Microbiology at Rockefeller.

Previous research had already shown that -- in general -- Ceftobiprole was highly effective against most clinical isolates of S. aureus. "Instead, we looked more carefully at the highly resistant cells that already occur in such clinical isolates at very low frequency -- maybe in one bacterium in every 1,000," says Tomasz. Ceftobiprole was able to kill these resistant cells.

Never before has an antibiotic been tested this way. "In the history of antibiotic development, an antibiotic arrives on the scene, and sooner or later resistant bacteria emerge," Tomasz says. "We sought to test in advance which would win this particular chess game: the new drug, or the bacteria that now cause human deaths."

In an ominous new "move" in this chess game, S. aureus strains with resistance to vancomycin (VRSA), a different class of antibiotics, also began to appear in hospitals in the United States. Ceftobiprole was also able to kill these new resistant VRSA strains.

The drug is effective because the chemists who developed Ceftobiprole managed to outwit the bacteria at their own game, Tomasz says. The broad-spectrum antibiotic was discovered by Basilea Pharmaceuticals, based in Basel, Switzerland, and is being developed in the U.S. and worldwide by Johnson & Johnson. The research was supported by Johnson & Johnson along with a grant from the U.S. Public Health Service.

Source: Rockefeller University

Explore further: Scientists generate first human stomach tissue in lab with stem cells

add to favorites email to friend print save as pdf

Related Stories

Will Apple Pay be mobile pay's kick-start?

1 hour ago

If anyone can get us to use our smartphones as wallets, it's Apple. That's what experts think about the recent launch of Apple Pay, the first mobile wallet to work on an iPhone.

Google execs discuss regulation, innovation and bobble-heads

3 hours ago

Eric Schmidt and Jonathan Rosenberg help run Google, one of the world's best-known, most successful - and most controversial - companies. They've just published a new book, "How Google Works," a guide to managing what they ...

Developing the battery of the future

3 hours ago

The search for the next generation of batteries has led researchers at the Canadian Light Source synchrotron to try new methods and materials that could lead to the development of safer, cheaper, more powerful, ...

Gamers' funding fuels meteoric rise of 'Star Citizen'

3 hours ago

Chris Roberts' brain spun out a grand vision: a rich, immersive galaxy; exquisite spaceships traversing between infinite star systems with thousands of computer gamers manning the cockpits, racing, dogfighting and defending ...

Recommended for you

Unlocking the secrets of pulmonary hypertension

13 hours ago

A UAlberta team has discovered that a protein that plays a critical role in metabolism, the process by which the cell generates energy from foods, is important for the development of pulmonary hypertension, a deadly disease.

New molecule sneaks medicines across the blood/brain barrier

18 hours ago

Delivering life-saving drugs across the blood-brain barrier (BBB) might become a little easier thanks to a new report published in the November 2014 issue of The FASEB Journal. In the report, scientists describe an antibo ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

menkaur
not rated yet Jul 03, 2008
beat - no
open new fighting front - yes
but it's a remarkable achievement

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.